Skip to main content

Limited Resources, Priorities, and Corruption

  • Chapter
  • First Online:
Medical Ethics in Clinical Practice
  • 1924 Accesses

Abstract

In this chapter, we discuss the situation in countries with a national healthcare system and do not cover countries with private healthcare insurance or those where services are paid out of pocket. Very few countries can meet all the costs of modern medicine for all their citizens. The three consequences of the gap between the available resources and the costs of modern medicine are limited access to costly medical interventions, waiting times for diagnostic and therapeutic interventions, and list of priorities. From the ethical standpoint, it is essential that all three of these issues are openly discussed and agreed within a wide circle including medical professionals and representatives of the lay community. In case of lack of democratic agreement and of clear rules, access to medical care may depend on the social and/or economic position of an individual. In a society based on solidarity, such a situation is contrary to the ethical principle of justice and may be considered to be a form of corruption.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Originator (also original) drugs are those that have been granted marketing authorization on the basis of studies done by the manufacturer that prove the drug’s safety, quality, and efficacy. Once the originator drug loses patent protection, another manufacturer can make and market a generic drug with the same active substance. Generic drugs are typically not tested in additional clinical studies and can be significantly cheaper.

  2. 2.

    In Slovenia, the physician can indicate one of the four levels of urgency when referring a patient to a specialist: urgent, very fast, fast, or regular.

  3. 3.

    In the drug information leaflet, the manufacturer writes: “We currently do not have sufficient data based on which we could recommend the use of Remifentanil during labor or Caesarean section. Remifentanil is transported through the placental membrane; analogues of Remifentanil can cause respiratory depression in newborns.” English anesthesiologist Prof. Felicity Reynolds Spencer, a leading expert, wrote that Remifentanil is “worse than useless” for managing labor pain and in many respects harmful to the newborn (personal communication, January 2, 2016).

Reference

  1. Calltorp J. Priority setting in health policy in Sweden and a comparison with Norway. Health Policy. 1999;50:1–22.

    Article  CAS  Google Scholar 

Suggested Reading

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zwitter, M. (2019). Limited Resources, Priorities, and Corruption. In: Medical Ethics in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-00719-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-00719-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-00718-8

  • Online ISBN: 978-3-030-00719-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics